FAIM
NBRV

Financial Advocates Investment Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Financial Advocates Investment Management’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-52
Closed -$17K – 561
2019
Q4 		$17K Buy
+52
New +$23.9K ﹤0.01% 509

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FNC
First National Corp Rockland, Massachusetts $527M AUM 12.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Financial Advocates Investment Management's NBRV Position: Q1 2020 in Review

Financial Advocates Investment Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2020, closing a stake of 52 shares — an estimated $17K sold.

Financial Advocates Investment Management first reported a position in NBRV in Q4 2019 and held it in 1 quarter. The position peaked at $17K in Q4 2019. 50 funds tracked by Wall St. Rank hold NBRV as of Q1 2020.

  • Financial Advocates Investment Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2020 after selling out during the quarter.
  • Financial Advocates Investment Management sold 52 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2020, an estimated $17K.
  • Financial Advocates Investment Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2019 and held it in 1 quarter.
  • Financial Advocates Investment Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $17K in Q4 2019.
  • 50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2020.

Based on Financial Advocates Investment Management's 13F filing for Q1 2020, filed 29 Apr 2020.